Skip to main content

Udenyca News

Coherus Announces FDA Approval of Udenyca Onbody™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Innovative design enables five-minute pegfilgrastim delivery time Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving...

FDA Approves Fylnetra (pegfilgrastim-pbbk), a Biosimilar to Neulasta

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- May 27, 2022 – Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has appr...

FDA Approves Udenyca (pegfilgrastim-cbqv), a Biosimilar to Neulasta

REDWOOD CITY, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) – Coherus BioSciences, Inc. (NASDAQ: CHRS), today announced that the U.S. Food and Drug Administration (FDA) has approved Udenyca...

FDA Approves Udenyca (pegfilgrastim-cbqv), a Biosimilar to Neulasta

REDWOOD CITY, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) – Coherus BioSciences, Inc. (NASDAQ: CHRS), today announced that the U.S. Food and Drug Administration (FDA) has approved Udenyca...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Neutropenia Associated with Chemotherapy

Udenyca patient information at Drugs.com